New hope for hepatitis delta: expanded access to bulevirtide

This study provides access to the drug bulevirtide (Hepcludex®) for people with chronic hepatitis delta virus infection who have compensated liver disease (with or without cirrhosis). Participants must meet specific health criteria, including a positive HDV RNA test. The goal is to offer treatment to eligible patients who may benefit from this antiviral therapy.